Additional immune checkpoint regulators with emerging clinical relevance include lymphocyte-activation gene 3 (LAG-3/CD223) expressed on activated T cells, NK cells and plasmacytoid DCs, and TIGIT expressed on effector T and NK cells, which binds to CD155 on antigen-presenting cells or tumor cells. Here, LAG3 is linked to neoplasm.